February 8, 2022
494th Edition, February 8, 2022
Trouble Viewing This Email: Click HereFebruary 08, 2022 FOUNDING MEMBER OF Geoffrey Lynn, co-founder Avedia, SVP,…
February 8, 2022
493rd Edition, February 1, 2022
Trouble Viewing This Email: Click HereFebruary 01, 2022 FOUNDING MEMBER OF BioHealth Innovation Announces Updates to…
February 7, 2022
Tyrell Rivers, Ph.D.
Dr. Tyrell Rivers is Executive Director of Corporate Development & Ventures at AstraZeneca, where he…
February 7, 2022
Ron Kurz
Ron Kurz, Senior Director / GM at Canon Virginia, Inc. (CVI) Ronald C. Kurz is…
February 7, 2022
Geoffrey Lynn, co-founder Avedia, SVP, Synthetic Immunotherapies, Vaccitech, joins BioTalk
Geoffrey Lynn, SVP, Synthetic Immunotherapies, Vaccitech, visits Rich Bendis to discuss his career from NIH,…
February 7, 2022
How Johns Hopkins Inventors’ Vision for Early Cancer Detection Got a $2.1B Boost – Johns Hopkins Technology Ventures
Johns Hopkins researchers Nickolas Papadopoulos, Ken Kinzler and Bert Vogelstein have spent their careers working…
February 7, 2022
2 technologies of which hospitals should be wary
Blockchain and "connected health" technology are two trends hospitals should not rush to adopt, according…
February 7, 2022
Arcellx Announces Pricing of Initial Public Offering – Arcellx
GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company…